Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
02 September, 2015 12:57 IST
Glenmark Q3 profit surges 4.75 times
Source: IRIS | 29 Jan, 2013, 04.28PM
Comments  |  Post Comment

Glenmark Pharmaceuticals reported a surge of 4.75 times in consolidated net profit to Rs 2,129.17 million for the quarter ended Dec. 31, 2012 as compared to Rs 448.24 million in the same period last year. During the quarter, the company received out-licensing revenue of Rs. 493.03 million from Forest Laboratories.

Consolidated revenue has increased by 33.96% to Rs 13.81 billion for the quarter ended  Dec. 31, 2012 from Rs 10.31 billion in the year ago period.

Revenue from the generics business was at Rs 5.80 billion, as against Rs 4.36 billion, a growth of 33%.

Glenmark Generics Inc., U.S.A. registered revenue from sale of finished dosage formulations was Rs 4.36 billion for the quarter ended Dec 31, 2012 against revenue of Rs 3.19 billion for the previous corresponding quarter, recording an increase of 36.83%.

''We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 % for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company,'' said Glenn Saldanha, chairman and MD, Glenmark Pharmaceuticals. (Q,N,C,F)*

''The option agreement with Forest Laboratories for the development of novel mPGES-1 inhibitors and the USFDA approval for Glenmark's in-licensed molecule - Crofelemer has come as a big boost and renewed validation for our world-class Drug Discovery apabilities. While the option agreement with Forest Labs marks our seventh outlicensing deal in the innovation R&D space; the USFDA approval for Crofelemer has paved the way for Glenmark becoming the first Indian company to launch an New Chemical Entity (NCE) across multiple geographies,'' he added.

Shares of the company unchanged to settle at Rs 504.05. The total volume of shares traded was 133,269 at the BSE (Tuesday).

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Related Articles
Suven commences phase-1 clinical trial of Alzheimer's drug - 02-Sep-2015 11:46
DLF climbs after it's arm partners with GIC to develop Delhi projects - 02-Sep-2015 11:38
RBI hikes FII limit to 50% in Info Edge - 02-Sep-2015 11:00
India Ratings affirms JK Bank at 'AA' - 02-Sep-2015 10:28
DLF arm partners with GIC to develop two projects in Delhi - 02-Sep-2015 10:23
Hero Motocorp two-wheeler sales drop 14% in August - 02-Sep-2015 10:03
Bajaj Auto sales up 2% in August - 02-Sep-2015 09:38
OMCs reduce ATF prices by 11.8% - 01-Sep-2015 19:45
OMCs reduce ATF prices by 11.8% - 01-Sep-2015 19:45
OMCs reduce ATF prices by 11.8% - 01-Sep-2015 19:45
Tata Motors sales flat at 40,680 units in August - 01-Sep-2015 17:09
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer